Home » Posts tagged with » Japan
Olympus to acquire US medical device firm Veran Medical Technologies for $340m

Olympus to acquire US medical device firm Veran Medical Technologies for $340m

Olympus Corporation has signed a deal worth up to $340 million to acquire Veran Medical Technologies (VMT), a Missouri-based provider of advanced medical devices specializing in interventional pulmonology. The Japanese optical products company will carry out the acquisition via its subsidiary Olympus Corporation of the Americas (OCA). It is said to be the latest in […]

Astellas, FibroGen get extended Roxadustat approval in Japan for anemia of CKD

Roxadustat approval – Astellas Pharma and FibroGen have secured approval for EVRENZO (roxadustat) in Japan for the treatment of anemia associated with chronic kidney disease (CKD) in adults, who are not on dialysis. The approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) is the second in the country for roxadustat through the […]

Continue reading …
Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis

Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission (EC) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. The approval of the once-daily, oral, JAK1 inhibitor is rheumatoid arthritis patients who showed inadequate response […]

Continue reading …
Japan-based Santen acquires US ophthalmic company Eyevance Pharmaceuticals

Santen acquisition of Eyevance : Santen Pharmaceutical, a Japanese pharma company specialized in ophthalmology, has acquired US ophthalmic company Eyevance Pharmaceuticals for $225 million in cash. The acquisition was undertaken by the company’s fully-owned subsidiary Santen Holdings U.S. Established only a couple of years ago, Eyevance Pharmaceuticals develops and commercializes topical ophthalmic products that target the […]

Continue reading …
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia

SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. Cenobamate was approved by the US Food and Drug Administration as an anti-seizure medication (ASM) under the brand name XCOPRI for the treatment of partial-onset seizures in adults. (Read here […]

Continue reading …
Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial

Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint of progression-free survival (PFS). The late-stage trial assessed the combination of NINLARO (ixazomib) with lenalidomide and dexamethasone in comparison to lenalidomide and dexamethasone plus placebo […]

Continue reading …
Takeda to sell select non-core assets to Cheplapharm for $562m

Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm for about $562 million. The portfolio to be offloaded to Cheplapharm is made up of non-core prescription pharma products in a range of therapeutic segments. This includes cardiovascular/metabolic and anti-inflammatory […]

Continue reading …
Takeda to divest consumer healthcare business to Blackstone for $2.3bn

Japanese pharma giant Takeda Pharmaceutical has agreed to sell its consumer healthcare business to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group and its affiliates (collectively Blackstone) for JPY 242 billion ($2.3 billion). The business being divested- Takeda Consumer Healthcare Company (TCHC) is focused on the consumer health care market […]

Continue reading …
Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan

US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former’s COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is said to be a stable, prefusion protein produced by using the recombinant protein nanoparticle technology of Novavax. The coronavirus vaccine candidate also contains the company’s Matrix‑M adjuvant. Takeda […]

Continue reading …
AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter’s DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), which is being developed for the treatment of multiple tumor types. Daiichi Sankyo is developing the antibody drug conjugate for multiple tumors […]

Continue reading …
Page 1 of 3123